In 2019, marketing approval was granted for oral semaglutide, the world’s first glucagon-like peptide-1 receptor agonist (GLP-1RA) approved for the treatment of type 2 diabetes, providing a promising new treatment option for people with diabetes. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.